利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.022 秒)

    Chimera (double) decoy
    1.
    发明授权
    Chimera (double) decoy 有权
    嵌合（双）诱饵

    公开(公告)号：US08067384B2

    公开(公告)日：2011-11-29

    申请号：US11662777

    申请日：2005-10-20

    申请人： Ryuichi Morishita ,  Toshio Ogihara ,  Motokuni Aoki ,  Takashi Miyake

    发明人： Ryuichi Morishita ,  Toshio Ogihara ,  Motokuni Aoki ,  Takashi Miyake

    IPC分类号： C12N15/11 ,  C12N15/113 ,  C12N15/115

    CPC分类号： C12N15/113 ,  A61K48/00 ,  C12N2310/13 ,  C12N2310/3519

    摘要： The present invention provides a prophylactic, ameliorative or therapeutic medicament for vascular restenosis, ischemic disease, allergic disease, inflammatory disease, autoimmune disease, or cancer metastasis, invasion (cancer metastasis/invasion) or cachexia based on the inhibitory action on a plural of transcriptional regulatory factor. A chimera (double) decoy of the present invention has plural transcriptional regulatory factor binding sequences in a single molecule thereof. Thus, it is able to inhibit the activity of plural transcriptional regulatory factors with a single molecule. For example, stenosis of an anastomosed site of an artificial blood vessel is caused by thickening of the vascular intima, and this is mainly caused by activation of cell proliferation by an inflammatory reaction occurring at the anastomosed site. Thus, thickening of vessel walls can be inhibited by simultaneously inhibiting two transcriptional regulatory factors involved in inflammation and cell proliferation by using the chimera decoy of the present invention.

    摘要翻译： 本发明提供了一种用于血管再狭窄，缺血性疾病，过敏性疾病，炎性疾病，自身免疫性疾病或癌症转移，侵袭（癌症转移/侵袭）或恶病质的预防，改善或治疗药物，其基于对多种转录的抑制作用 监管因素。 本发明的嵌合体（双）诱饵在其单个分子中具有多个转录调节因子结合序列。 因此，能够用单个分子抑制多个转录调节因子的活性。 例如，人造血管的吻合部位的狭窄是由血管内膜的增厚引起的，这主要是由在吻合部位发生的炎性反应的细胞增殖的激活引起的。 因此，通过使用本发明的嵌合体诱饵同时抑制涉及炎症和细胞增殖的两种转录调节因子，可以抑制血管壁的增厚。

    Chimeric (Double) Decoy
    2.
    发明申请
    Chimeric (Double) Decoy 有权
    嵌合（双）诱饵

    公开(公告)号：US20070259826A1

    公开(公告)日：2007-11-08

    申请号：US11662777

    申请日：2005-10-20

    申请人： Ryuichi Morishita ,  Toshio Ogihara ,  Motokuni Aoki ,  Takashi Miyake

    发明人： Ryuichi Morishita ,  Toshio Ogihara ,  Motokuni Aoki ,  Takashi Miyake

    IPC分类号： A61K31/713 ,  A61K31/70 ,  A61K31/7105 ,  A61P17/06 ,  A61P35/04 ,  A61P41/00 ,  C07H21/02 ,  C07H21/04 ,  A61P9/10 ,  A61P37/08 ,  A61P29/00 ,  A61P17/00 ,  A61K31/711

    CPC分类号： C12N15/113 ,  A61K48/00 ,  C12N2310/13 ,  C12N2310/3519

    摘要： The present invention provides a prophylactic, ameliorative or therapeutic medicament for vascular restenosis, ischemic disease, allergic disease, inflammatory disease, autoimmune disease, or cancer metastasis, invasion (cancer metastasis/invasion) or cachexia based on the inhibitory action on a plural of transcriptional regulatory factor. A chimera (double) decoy of the present invention has plural transcriptional regulatory factor binding sequences in a single molecule thereof. Thus, it is able to inhibit the activity of plural transcriptional regulatory factors with a single molecule. For example, stenosis of an anastomosed site of an artificial blood vessel is caused by thickening of the vascular intima, and this is mainly caused by activation of cell proliferation by an inflammatory reaction occurring at the anastomosed site. Thus, thickening of vessel walls can be inhibited by simultaneously inhibiting two transcriptional regulatory factors involved in inflammation and cell proliferation by using the chimera decoy of the present invention.

    摘要翻译： 本发明提供了一种用于血管再狭窄，缺血性疾病，过敏性疾病，炎性疾病，自身免疫性疾病或癌症转移，侵袭（癌症转移/侵袭）或恶病质的预防，改善或治疗药物，其基于对多种转录的抑制作用 监管因素。 本发明的嵌合体（双）诱饵在其单个分子中具有多个转录调节因子结合序列。 因此，能够用单个分子抑制多个转录调节因子的活性。 例如，人造血管的吻合部位的狭窄是由血管内膜的增厚引起的，这主要是由在吻合部位发生的炎性反应的细胞增殖的激活引起的。 因此，通过使用本发明的嵌合体诱饵同时抑制涉及炎症和细胞增殖的两种转录调节因子，可以抑制血管壁的增厚。

    Pharmaceutical composition containing decoy and use of the same
    5.
    发明申请
    Pharmaceutical composition containing decoy and use of the same 审中-公开
    含有诱饵的药物组合物及其用途

    公开(公告)号：US20060263422A1

    公开(公告)日：2006-11-23

    申请号：US11442585

    申请日：2006-05-26

    申请人： Ryuichi Morishita ,  Motokuni Aoki ,  Toshio Ogihara ,  Tomio Kawasaki ,  Hirofumi Makino

    发明人： Ryuichi Morishita ,  Motokuni Aoki ,  Toshio Ogihara ,  Tomio Kawasaki ,  Hirofumi Makino

    IPC分类号： A61K48/00 ,  A61K9/127

    CPC分类号： A61K9/127 ,  A61K31/711 ,  A61K38/08 ,  A61K38/1709 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  A61K48/0008 ,  A61K48/005 ,  C12N15/113 ,  C12N15/86 ,  C12N2310/13 ,  C12N2710/10343 ,  C12N2740/13043

    摘要： A pharmaceutical composition is provided for treatment and/or prevention of a disease, a disorder and/or a condition caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. Alternatively, the disease is a disease associated with eosinophilic abnormality (e.g., asthma, vascular diseases, allergic diseases, parasite diseases). The pharmaceutically acceptable carrier may be a hydrophilic polymer, a liposome, or the like.

    摘要翻译： 提供了用于治疗和/或预防由NF-κB或ets控制的基因的表达引起的疾病，病症和/或病症的药物组合物。 组合物包含至少一种诱饵和药学上可接受的载体。 诱饵是NF-kappaB诱饵，ets诱饵，或NF-kappaB和ets的嵌合体诱饵。 该疾病是脑动脉瘤，癌症，马凡氏综合征，主动脉分离，血管成形术后再狭窄，慢性关节风湿病，哮喘，特应性皮炎，肾炎，肾衰竭或斑块破裂。 或者，该疾病是与嗜酸粒细胞异常（例如，哮喘，血管疾病，过敏性疾病，寄生虫疾病）相关的疾病。 药学上可接受的载体可以是亲水性聚合物，脂质体等。

    Topical administration of NF-kappaB decoy to treat atopic dermatitis
    7.
    发明授权
    Topical administration of NF-kappaB decoy to treat atopic dermatitis 有权
    NF-κB诱饵的局部给药治疗特应性皮炎

    公开(公告)号：US09012417B2

    公开(公告)日：2015-04-21

    申请号：US10468717

    申请日：2002-02-06

    申请人： Ryuichi Morishita ,  Motokuni Aoki ,  Toshio Ogihara ,  Yasufumi Kaneda ,  Hiroshige Nakamura

    发明人： Ryuichi Morishita ,  Motokuni Aoki ,  Toshio Ogihara ,  Yasufumi Kaneda ,  Hiroshige Nakamura

    IPC分类号： A61K48/00 ,  A61K31/711 ,  A61K38/17 ,  C12N15/113

    CPC分类号： A61K31/711 ,  A61K38/1709 ,  C12N15/113 ,  C12N2310/13

    摘要： A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The at least one decoy may be an oligonucleotide including at least two decoys bonded to each other, the at least two decoys being selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The skin disease may be atopic dermatitis, psoriasis vulgaris, contact dermatitis, keloid, bedsore, ulcerative colitis, or Crohn's disease.

    摘要翻译： 一种用于对皮肤病进行治疗的药物组合物，所述药物组合物包含至少一种诱饵和药学上可接受的载体。 所述至少一个诱饵可以选自NF-和kgr B诱饵，STAT-1诱饵，GATA-3诱饵，STAT-6诱饵，AP-1诱饵和Ets诱饵。 所述至少一个诱饵可以是包含至少两个彼此键合的诱饵的寡核苷酸，所述至少两个诱饵选自由NF-和κB诱饵，STAT-1诱饵，GATA-3诱饵 ，STAT-6诱饵，AP-1诱饵和Ets诱饵。 皮肤病可能是特应性皮炎，寻常型牛皮癣，接触性皮炎，瘢痕疙瘩，褥疮，溃疡性结肠炎或克罗恩病。

    Pharmaceutical composition containing decoy and method of using the same
    8.
    发明申请
    Pharmaceutical composition containing decoy and method of using the same 审中-公开
    含有诱饵的药物组合物及其使用方法

    公开(公告)号：US20090105183A1

    公开(公告)日：2009-04-23

    申请号：US12314009

    申请日：2008-12-02

    申请人： Ryuichi Morishita ,  Motokuni Aoki ,  Toshio Ogihara ,  Yasufumi Kaneda ,  Hiroshige Nakamura

    发明人： Ryuichi Morishita ,  Motokuni Aoki ,  Toshio Ogihara ,  Yasufumi Kaneda ,  Hiroshige Nakamura

    IPC分类号： A61K31/7088 ,  A61P17/00

    CPC分类号： A61K31/711 ,  A61K38/1709 ,  C12N15/113 ,  C12N2310/13

    摘要： A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The at least one decoy may be an oligonucleotide including at least two decoys bonded to each other, the at least two decoys being selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The skin disease may be atopic dermatitis, psoriasis vulgaris, contact dermatitis, keloid, bedsore, ulcerative colitis, or Crohn's disease.

    摘要翻译： 一种用于对皮肤病进行治疗的药物组合物，所述药物组合物包含至少一种诱饵和药学上可接受的载体。 所述至少一个诱饵可以选自NF-κB诱饵，STAT-1诱饵，GATA-3诱饵，STAT-6诱饵，AP-1诱饵和Ets诱饵。 所述至少一个诱饵可以是包含至少两个彼此键合的诱饵的寡核苷酸，所述至少两个诱饵选自NF-κB诱饵，STAT-1诱饵，GATA-3诱饵， STAT-6诱饵，AP-1诱饵和Ets诱饵。 皮肤病可能是特应性皮炎，寻常型牛皮癣，接触性皮炎，瘢痕疙瘩，褥疮，溃疡性结肠炎或克罗恩病。

    Compositions and methods for angiogenic therapy utilizing genes encoding ets-1
    10.
    发明授权
    Compositions and methods for angiogenic therapy utilizing genes encoding ets-1 有权
    使用编码ets-1的基因进行血管生成治疗的组合物和方法

    公开(公告)号：US07994151B2

    公开(公告)日：2011-08-09

    申请号：US12435335

    申请日：2009-05-04

    申请人： Ryuichi Morishita ,  Hiromi Koike ,  Tadashi Tanabe ,  Motokuni Aoki

    发明人： Ryuichi Morishita ,  Hiromi Koike ,  Tadashi Tanabe ,  Motokuni Aoki

    IPC分类号： A61K48/00 ,  A01N63/00 ,  A01N65/00 ,  C12N15/00 ,  C07H21/04

    CPC分类号： A61K38/52 ,  A61K31/5585 ,  A61K31/711 ,  A61K38/1709 ,  A61K38/1833 ,  A61K38/1858 ,  A61K48/00 ,  A61K2300/00

    摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets 1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

    摘要翻译： 本发明提供：（1）血管生成治疗用药物组合物，其含有选自具有血管扩张作用和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分，以及生成它们的物质; 和编码血管生成因子的基因; （2）增强编码血管生成因子的基因的血管生成作用的药剂，其含有选自具有血管舒张作用和/或血小板聚集抑制作用的物质和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分; （3）含有前列环素合酶基因作为活性成分的血管生成剂; （4）含有ets-1基因和编码血管生成因子的另一基因作为活性成分的用于血管生成治疗的药物组合物; （4）含有ets1基因作为增强编码血管生成因子的另一基因的血管生成作用的活性成分的药剂; 和（5）含有ets-1基因作为活性成分的血管生成剂。